Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. Among authors: milata j. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A. Sands BE, et al. Among authors: milata j. Inflamm Bowel Dis. 2024 Mar 9:izae024. doi: 10.1093/ibd/izae024. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 38459910
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
Kobayashi T, Matsuoka K, Watanabe M, Hisamatsu T, Hirai F, Milata J, Li X, Morris N, Arora V, Ishizuka T, Matsuo K, Satoi Y, Milch C, Hibi T. Kobayashi T, et al. Among authors: milata j. Intest Res. 2024 Apr;22(2):172-185. doi: 10.5217/ir.2023.00043. Epub 2024 Apr 25. Intest Res. 2024. PMID: 38720466 Free PMC article.
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A. Sands BE, et al. Among authors: milata j. Inflamm Bowel Dis. 2024 Oct 25:izae253. doi: 10.1093/ibd/izae253. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39448057
Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.
Clemow D, Radawski C, Milata J, Alaka K, Gibble TH, Schaum A, Ezennia O, Martinez N, Szaloki T, Ito Y, Rodriguez D, Kirk K. Clemow D, et al. Among authors: milata j. Crohns Colitis 360. 2024 Oct 4;6(4):otae054. doi: 10.1093/crocol/otae054. eCollection 2024 Oct. Crohns Colitis 360. 2024. PMID: 39473630 Free PMC article.
11 results